RankAlpha logo
Back to Rankings

GRCE

Grace TherapeuticsC
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-03
View Chart
Current thesis
The bull case is that the CRL is remediable rather than thesis-breaking: the company still centers the story on GTx-104, the April 2026 presentation implies management believes the cited CMC and non-clinical items can be addressed, and a successful Type A meeting could reopen a resubmission path.
Posture
Mixed
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta -4.3.
What can break
Cash runway looked adequate as of the February 2026 filing, but prolonged remediation could force dilutive financing.
Momentum
70
Value
41
Sentiment
53
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $2.10 · Bull $5.50 · Bear $0.90
Data freshness
Prices
As of 2026-06-03
Fundamentals
As of 2026-06-02 • Vendor: Data Vendor v1
Scores
As of 2026-06-03 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-28 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-06-03
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $11.50
Why
Momentum70 · Δ7d -4.3
Value41 · Δ7d +0.0
Sentiment53 · Δ7d +16.3
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Momentum · See technicals
Momentum
70
34% active weight
Current posture
7d trendSoftening
Δ7d
-4.3
Δ21d
-17.6
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
+0.2
Sentiment
53
33% active weight
Current posture
7d trendImproving
Δ7d
+16.3
Δ21d
-41.8
Why this grade

Composite grade C. Momentum 69.8 / Value 41.1 / Sentiment 52.7

Fundamentals (TTM)
As of 2026-06-02
Market Cap
$38.69M
Beta
0.77
Shares Out
15.47M
P/E (TTM) · Derived
-3.2
P/S (TTM)
-
P/FCF (TTM) · Derived
-2.98
Rev YoY
-
EPS YoY
+80.3%
Gross Margin
-
Op Margin
-
Net Debt
-$22.13M
Current Ratio
13.89
As of 2026-06-03 • Updated nightlySource: Internal modelMethodology